|
|
|
|
Vol. 11, Issue 6, 2161-2173, June 2000
Department of Cell Biology and Neuroscience, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9039
Submitted December 22, 1999; Revised March 17, 2000; Accepted March 30, 2000| |
ABSTRACT |
|---|
|
|
|---|
The nature of kinesin interactions with membrane-bound organelles and mechanisms for regulation of kinesin-based motility have both been surprisingly difficult to define. Most kinesin is recovered in supernatants with standard protocols for purification of motor proteins, but kinesin recovered on membrane-bound organelles is tightly bound. Partitioning of kinesin between vesicle and cytosolic fractions is highly sensitive to buffer composition. Addition of either N-ethylmaleimide or EDTA to homogenization buffers significantly increased the fraction of kinesin bound to organelles. Given that an antibody against kinesin light chain tandem repeats also releases kinesin from vesicles, these observations indicated that specific cytoplasmic factors may regulate kinesin release from membranes. Kinesin light tandem repeats contain DnaJ-like motifs, so the effects of hsp70 chaperones were evaluated. Hsc70 released kinesin from vesicles in an MgATP-dependent and N-ethylmaleimide-sensitive manner. Recombinant kinesin light chains inhibited kinesin release by hsc70 and stimulated the hsc70 ATPase. Hsc70 actions may provide a mechanism to regulate kinesin function by releasing kinesin from cargo in specific subcellular domains, thereby effecting delivery of axonally transported materials.
| |
INTRODUCTION |
|---|
|
|
|---|
Translocation of organelles along microtubules by the kinesin
heterotetramer requires several discrete activities (Brady, 1995
), all
of which may be sites for regulating kinesin-based processes. Although
hydrolysis of ATP, binding to microtubules, and generation of force
have received considerable attention to date, relatively little
information is available about interactions between kinesin and
membrane-bound organelles (MBOs). Curiously, although kinesin is
generally thought to mediate transport of MBOs along microtubules, it
is typically purified from soluble fractions of tissue extracts. In
subcellular fractionation studies, ~70% of cellular kinesin was
recovered in soluble fractions (Hollenbeck, 1989
). However, the
presence of a significant pool of soluble kinesin inside cells is
problematic, because kinesin isolated in this way is a
microtubule-activated ATPase. Soluble kinesin in cells might be
expected to deplete cellular ATP through this ATPase activity or to
interfere with MBO-associated motors sterically by competing for
microtubule-binding sites. One possibility is that a mechanism exists
to limit the activity of soluble kinesin in vivo. Several
groups have provided evidence that conformational changes in soluble
kinesin bring the tail of kinesin in contact with its head and inhibits
microtubule-activated ATPase activity (Hackney et al., 1992
;
Verhey et al., 1998
; Coy et al., 1999
; Friedman
and Vale, 1999
). However, this inhibition by folding of soluble kinesin
is typically seen in low-ionic-strength buffers and is not significant
in buffers with intracellular ionic strength and pH (Hirokawa et
al., 1989
). Alternatively, levels of soluble kinesin in vivo might
be substantially lower than fractionation studies imply.
Several lines of evidence indicate that most kinesin is bound to MBOs
in intact cells (Brady, 1995
; Brady and Sperry, 1995
). Kinesin
immunoreactivity is associated with detergent-soluble, punctate
structures in close proximity to microtubules, with little evidence of
an unbound fraction (Pfister et al., 1989b
). When a
nonhydrolyzable analogue of ATP, adenylyl 5'-imidodiphosphate (AMP-PNP), is perfused into squid axoplasm, all MBOs stop moving and
remain attached to microtubules through kinesin links (Brady, 1985
;
Lasek and Brady, 1985
), indicating both that kinesin is associated with
these MBOs and that kinesin attachment to MBOs is relatively stable.
Similarly, pulse labeling of kinesin in axonal transport demonstrated
that kinesin travels in fast axonal transport with MBO with little or
no kinesin detectable in slow axonal transport with soluble,
cytoplasmic proteins (Elluru et al., 1995
). Finally, kinesin
still bound to MBOs after the initial fractionation is highly resistant
to in vitro treatments, including high salt and carbonate, that release
most peripheral membrane proteins (Leopold et al., 1992
;
Schnapp et al., 1992
).
Such considerations suggest that regulation of kinesin binding to MBOs could be an important physiological pathway for regulating kinesin-based transport of MBOs. Although little is known about regulation of kinesin binding to membranes, the tightness of binding suggested that release of kinesin from MBOs might involve an energy-dependent step, presumably mediated by one or more enzymatic activities. Active removal of kinesin from membranes could be increased during homogenization because of disruption of intracellular compartments. Such disruptions may activate cellular processes that are kept under tight control in the intact cell and thereby may increase soluble fractions of kinesin in tissue extracts. Two types of experiments were undertaken to test the hypothesis that membrane-bound kinesin is released during homogenization and extraction of tissues. First, whole-cell detergent extraction was combined with immunofluorescence to compare the behavior of kinesin with proteins known to be soluble in vivo. If the majority of cellular kinesin is in a soluble cytoplasmic pool, then the soluble kinesin fraction should behave like soluble marker proteins. Conditions that effectively extract all soluble cytoplasmic markers had minimal effect on kinesin immunolocalization. Second, the fraction of tissue kinesin that remained bound to vesicles was assayed after homogenization in the presence of various enzyme inhibitors. If kinesin release is an active process, then inhibition of the relevant enzymatic activities should inhibit release. Homogenization with buffers containing millimolar levels of either a sulfhydryl modifying agent (N-ethylmaleimide [NEM]) or a chelator of divalent cations (EDTA) significantly increased the percent of cellular kinesin in membrane fractions.
Previously, an antibody directed against the tandem repeat domain of
kinesin light chains (KLCs) was found to release kinesin from MBOs.
This led to reexamination of sequences in the tandem repeat domain.
Identification of motifs characteristic of the J-domain in DnaJ, a
cofactor for hsp70 chaperones (Cyr et al., 1994
; Kelley,
1998
), suggested a role for members of this chaperone family.
Incubation of MBOs with purified hsc70 indicated that hsc70 released
kinesin from MBOs in a nucleotide-dependent and NEM-sensitive manner.
These results suggest that kinesin in vivo is tightly bound to MBO, but
activation of hsc70 during homogenization releases a large fraction of
bound kinesin into the supernatant. Consistent with this, treatment of
permeabilized, unfixed cells with purified hsc70 led to a reduction in
kinesin immunoreactivity. The hsc70 pathway may serve as a mechanism
for regulating kinesin function by releasing kinesin from MBOs in
specific subcellular domains, much as hsc70 is thought to remove
clathrin coats from coated vesicles (Ungewickell et al.,
1995
; Holstein et al., 1996
; Ungewickell et al.,
1997
), and other hsp70 family members mediate a variety of
protein-membrane interactions (Horst et al., 1997
; Terada
et al., 1997
; Zimmermann, 1998
).
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
The following cell lines were used: BHK21 wt (kidney cell line),
BHK21 stably transfected with green fluorescent protein (GFP) under the
control of the cytomegalovirus promoter (a gift from Z. Min), and 3T3 (mouse fibroblast cell line). Four chamber culture slides (Becton Dickinson, Franklin Lakes, NJ) were coated with poly-L-lysine (0.8 mg/ml in water; Sigma, St. Louis, MO)
for 1 h at room temperature and then washed three times with
water. Forty-eight hours before extraction, cells were plated at
densities of 2500-5000 cells/cm2 in Dulbecco's
modified Eagle's medium supplemented with 5% FBS and a mixture of
antibiotics. Immediately before detergent treatment, cells were rinsed
twice with 37°C PHEM buffer (60 mM 1,4-piperazinediethanesulfonic acid, 25 mM HEPES, 10 mM EGTA, and 2 mM MgCl2, pH
7.4) to remove serum and debris. Cells were then extracted for 4 min at
37°C with various concentrations of either Triton X-100 (0.01-1%;
Sigma), or digitonin (0.05-0.2%; Calbiochem, La Jolla, CA) freshly
made in PHEM supplemented with 1 mM GTP, 10 µM Taxol, and protease inhibitors (20 mM AEBSF, 200 mg/ml aprotinin, 100 mM pepstatin, and 1 mM leupeptin). Digitonin extraction buffers were also
supplemented with 5 mM EDTA (Mackall et al., 1979
).
Unextracted controls were incubated in supplemented PHEM for 4 min
before fixation. Cells treated with hsc70 were first extracted with
0.01% Triton X-100 for 1 min in PHEM (as above). Then the solution was
replaced with a fresh aliquot of 0.01% Triton X-100 containing PHEM
supplemented with 200 µM ATP, 10 mM MgCl2, and
purified bovine hsc70, and cells were extracted for an additional 4 min.
At the end of detergent incubations, cells were fixed in 2% paraformaldehyde and 0.01% glutaraldehyde in PHEM for 10 min at 37°C. Fixed cells were rinsed in PBS and then extracted in 0.6% Triton X-100 and PBS for 20 min, except that GFP-transfected cells were extracted in 0.2% Triton X-100 and PBS for 10 min. Before application of primary antibodies, cells were incubated in blocking solution (2.5% gelatin, 2.5% BSA, and 0.01% Na azide in PBS) for 1 h at room temperature. Primary and secondary antibodies were diluted in blocking solution. Primary antibodies were incubated at 4°C for ~16 h, whereas secondary antibodies were incubated for 45 min at room temperature. We used the following antibodies: rabbit anti-tubulin polyclonal antibody (Sigma T-3626) at 1:200; H2 anti-kinesin mouse monoclonal antibody at 5-20 µg/ml; goat anti-rabbit immunoglobulin G-Texas Red (Molecular Probes, Eugene, OR) at a dilution of 1:500; and goat-anti-mouse Oregon Green 488 at a dilution of 1:500 (Molecular Probes). After incubation with antibodies, cells were washed in PBS. After additional washes in 50 mM Tris, pH 8.0, slides were incubated with either a 1:400 dilution of To-Pro3 (Molecular Probes) for 15 min or a 1 µg/ml dilution of Hoechst dye (Aldrich Chemicals, St. Louis, MO) for 2 min and then rinsed with 50 mM Tris, pH 8.0. Slides were coversliped with ProLong antifade (Molecular Probes) or Gel/Mount (Biomedia, Foster City, CA). GFP, Texas Red immunofluorescence, and To-Pro3 or Hoechst fluorescence were visualized on a Zeiss (Thornwood, NY) Axiovert microscope using either a 40× (numerical aperture, 1.4) or a 63× (numerical aperture, 1.3) objective. Images were acquired either with a Bio-Rad (Hercules, CA) confocal laser scanning microscope or with a cooled charge-coupled device camera (ORCA; Hamamatsu, Hamamatsu City, Japan) controlled by Openlab Software (Improvision, Lexington, MA). Images were processed for presentation in Adobe Photoshop (Adobe Systems, Mountain View, CA). All images shown in the same panel were altered for contrast identically.
Microsomal vesicles were purified by homogenizing fresh bovine brains
in 5 volumes of homogenization buffer (HB; 300 mM sucrose, 10 mM HEPES,
pH 7.4, 5 mM MgCl2, and protease inhibitor
mixture [1 mM -4-(2-aminoethyl)benzenesulfonyl fluoride and 10 µg/ml
leupeptin, pepstatin, and aprotinin]). As indicated, HB was used
without additions, with NEM (0.1-5 mM), or with EDTA (5 mM) added to
buffer before homogenization. For NEM experiments, the suspension was centrifuged 15 min at 39,800 × g. This 39,800 × g pellet (V1) was resuspended in homogenization buffer by 10 passages through a 25-gauge hypodermic needle to disperse vesicles for
further analysis. The 39,800 × g supernatant was
centrifuged 40 min at 120,000 × g. The supernatant was
layered onto 600 mM sucrose in 10 mM HEPES, pH 7.4, and centrifuged for
2 h at 260,000 × g. The 260,000 × g pellet (V2) was resuspended in homogenization buffer as
described above. Vesicle samples were either processed for immunoblots or used for release assays. For quantitative
immunoblots, the supernatant (S) and vesicle fractions (V1
and V2) were probed for the presence of kinesin with the H2 antibody as
described previously (Pfister et al., 1989b
). Primary
antibodies were detected by 125I-protein A, and
the amount of kinesin in different fractions was quantitated with a
Molecular Dynamics (Sunnyvale, CA) PhosphorImager after overnight
exposure of screens.
For quantitative and qualitative comparisons between NEM and EDTA
treatments, this protocol was modified to generate a single vesicle
fraction that retained a lower percentage of kinesin. Brains were
homogenized in a buffer containing 320 mM sucrose and 10 mM HEPES, pH
7.4, and homogenates were centrifuged at 11,000 × g
maximum for 8 min to eliminate debris, nuclei, and mitochondria. Three
milliliters of each supernatant were taken from each tube and
centrifuged for 1 h at 200,000 × g max in a
Beckman Instruments (Palo Alto, CA) TLA.100.3 ultracentrifuge
rotor. After recovering the soluble fraction, the 200,000 × g pellets were resuspended by brief sonication in 1.5 ml of
HB. Protein concentration was measured by the Coommasie blue assay
(Pierce, Rockford, IL). Equal amounts (50 µg) of protein from each
fraction were separated by SDS-PAGE and transferred to a ZetaProbe
nylon membrane (Bio-Rad) 16 h at 25 V in 10 mM CAPS buffer, pH 11. Chemiluminescent assays and quantitative inmunoblots were performed as
described previously (Stenoien and Brady, 1997
). The amounts of
kinesin, hsc70, synaptophysin, and other proteins were quantitated with
a Molecular Dynamics PhosphorImager after overnight exposure of
screens. Monoclonal antibodies against hsc70 and synaptophysin were
purchased from StressGen (Victoria, BC). Secondary antibodies
were from Jackson ImmunoResearch (West Grove, PA).
The effects of hsc70 on the kinesin bound to microsomal vesicles (V2) were evaluated by incubating at a concentration of 1 mg/ml total vesicle protein with or without hsc70 for 30 min at 37°C in release buffer (HB plus 75 mM KCl). Hsc70 was used at concentration of 10 µg/ml for a molar ratio of 2:1 for hsc70:kinesin. After centrifugation over 600 mM sucrose in 10 mM HEPES, pH 7.4, at 260,000 × g, the supernatants and pellets were probed for the presence of kinesin using the H2 antibody on quantitative immunoblots. Antibodies were detected using 125I-labeled protein A and analyzed by PhosphorImager. The effects of NEM on hsc70-mediated release of endogenous kinesin were determined by addition of NEM (2 mM) to V2 vesicles in vitro either at the same time as hsc70 (time 0) or at different intervals after hsc70. To control for nonspecific effects of the NEM vehicle, the action of NEM on free sulfhydryl groups was blocked by simultaneous addition of dithiothreitol (DTT; 2 mM).
To evaluate the ability of different KLC constructs to affect
hsc70-mediated release of kinesin from vesicles, varying concentrations of recombinant proteins were added to purified microsomal vesicles (1 mg/ml total vesicle protein) with hsc70 at a concentration of 10 µg/ml (a molar ratio of 2:1 for hsc70:kinesin) for 30 min at 37°C.
Four different constructs were generated: glutathione S-transferase (GST; no insert), GST-LCA (full-length KLC1),
GST-TR1 (two tandem repeats), and GST-TR2 (four tandem repeats). The
molar ratios for fusion protein to hsc70 ranged from 0.25 to 8:1. To determine whether different KLC constructs differed in their ability to
bind hsc70, activation of hsc70 ATPase was assayed. Bovine brain hsc70
(1 µM) was incubated in a volume of 10 µl containing 0.2 mM
[
-32P]ATP with or without 2 µM GST-LCA or
GST-TR1 or GST alone for 1 h at 37°C in ATPase assay buffer (75 mM KCl, 5 mM MgCl2, 10 mM HEPES, pH 7.4, and
protease inhibitor mixture). At given time intervals, an aliquot
(0.5-0.7 µl) was withdrawn and spotted on polyethyleneimine-cellulose plates (Aldrich, Milwaukee, WI).
After developing in 0.5 M LiCl and 1 M formic acid, the spots on the chromatograms corresponding to [32P]phosphate
and [
-32p]ATP were excised, and the amount
of radioactivity was measured. The ATP hydrolyzed was expressed as the
percent radioactivity in phosphate as a fraction of total radioactivity
calculated from the sum of radioactivity in phosphate and ATP.
| |
RESULTS |
|---|
|
|
|---|
Differential detergent extraction was used to evaluate the
extractability of kinesin in cultured cells. Brief extraction of cells
with 0.015% digitonin creates holes in the plasma membrane with
minimal effects on intracellular organelles (Mackall et al., 1979
; Womack et al., 1983
; Ramsby and Makowski, 1998
).
Cultured cells extracted under these conditions release 90-100% of
traditional cytosolic markers such as lactate dehydrogenase and
carbonic anhydrase, but mitochondrial, lysosomal, and endoplasmic
reticulum markers are retained (Ramsby et al., 1994
). The
proteins released by digitonin treatment include myosin II, calpastatin
and other proteins >300 kDa in molecular mass (Weigel et
al., 1983
; Ramsby et al., 1994
). In contrast,
extraction of cells with Triton X-100 solubilizes many plasma membrane
and intracellular organelle membrane proteins in a time- and
concentration-dependent manner (Ramsby and Makowski, 1998
).
The behavior of kinesin during detergent extractions was compared with
that of a protein known to be soluble in vivo. BHK21 cells
constitutively expressing GFP were fixed directly or extracted before
fixation with either Triton X-100 or digitonin (Figure 1). When fixed without extraction GFP was
retained in the cell, but even the mildest detergent treatments led to
rapid loss of cytoplasmic GFP, leaving only a small residual fraction
in nuclei. Comparison between GFP and kinesin distributions in
unextracted cells suggested that these two proteins did not colocalize.
GFP permeated the cell, matching well to cell boundaries and thickness, but kinesin immunoreactivity appeared to be more restricted, perhaps enriched in selected cellular domains.
|
Digitonin extraction before fixation revealed more striking differences
between GFP and kinesin localization (Figure 1). Virtually all GFP was
extracted from cytoplasmic domains within 4 min, leaving only a weak
signal in the nucleus. In contrast, the bulk of the kinesin remained as
discrete structures that were often closely apposed to microtubules in
double-label studies. Significant punctate kinesin immunoreactivity
remains even after more stringent extractions using Triton X-100 under
conditions in which intracellular organelles begin to be extracted
(Ramsby and Makowski, 1998
). Although kinesin immunoreactivity appeared
reduced with Triton X-100 treatment (Figure 1), much kinesin remained
as punctate structures. Longer extractions and higher concentrations of
Triton X-100 that disrupt internal membranes substantially reduced
kinesin immunoreactivity ( Morfin et al., 2000
;
Pfister et al., 1989b
). Triton X-100 extraction also
eliminated essentially all cytoplasmic GFP but was no more effective
than digitonin in removing nuclear GFP. Although immunofluorescence methods are semiquantitative, they demonstrated that most kinesin immunoreactivity is resistant to treatments that release cytosolic proteins.
A more quantitative measure of kinesin bound to MBOs can be
obtained by subcellular fractionation. Kinesin levels were evaluated by
quantitative immunoblots of two purified organelle
fractions (V1 and V2) and the supernatant (S) using standard cell
fractionation methods. Consistent with previous reports (Hollenbeck,
1989
), ~70% of cellular kinesin was present in the supernatant with
control buffers (Figure 2a). A wide range
of buffer conditions and enzyme inhibitors were evaluated for an
ability to affect the partitioning of kinesin between membrane and
soluble fractions. Two treatments significantly increased the amount of
kinesin in membrane fractions: NEM, a sulfhydryl modifying agent, and
EDTA, a chelator of divalent cations. Both were effective at millimolar
concentrations when added to homogenization buffers.
|
Addition of NEM to homogenization buffer before extraction alkylates
any free sulfhydryls that become accessible during homogenization and
inhibits enzyme activities requiring free sulfhydryls. Millimolar NEM
in the homogenization buffer increased the amount of total protein in
both V1 and V2 fractions only ~5%. In contrast, the amount of
kinesin associated with V1 and V2 membrane fractions increased
approximately threefold, going from ~0.5% to ~1.5% of total
protein. Under these conditions, >90% of recovered kinesin partitioned with vesicle fractions after NEM treatment (Figure 2),
compared with 30% of total kinesin in vesicle fractions under standard
conditions. Kinesin associated with MBOs after NEM treatment remained
bound through sucrose gradient fractionation, indicating that increased
membrane-bound kinesin with NEM treatment was not due to aggregation of
soluble kinesin. Consistent with this, in vitro studies on inhibition
of kinesin ATPase, microtubule binding and gliding assays by NEM,
showed that NEM-treated kinesin does not aggregate but remains soluble
(Pfister et al., 1989a
; Sickles et al., 1996
).
These experiments indicate that NEM inhibits kinesin release from MBOs
during homogenization and suggested that at least one NEM-sensitive
pathway in cytoplasmic extracts releases kinesin from MBOs during homogenization.
A comparable increase of kinesin in membrane fractions was produced by
addition of 5 mM EDTA to homogenization buffers. In Figure
3a, the upper histogram shows that NEM,
EDTA, or the combination of NEM and EDTA treatments had little effect
on the total amount of protein in cytosolic and sonicated membrane
fractions. Similarly, none of these treatments altered the distribution
of either hsc70, a predominantly cytoplasmic protein, or synaptophysin,
an integral membrane protein (Figure 3b). However, the lower histogram
shows that treatment with either NEM (51%) or EDTA (54%) more than
doubled the amount of kinesin in membrane fractions compared with
control buffers (26%). Adding both NEM and EDTA to homogenization
buffer increased the amount of kinesin in membrane fractions to nearly 80% (Figure 3). The fact that NEM and EDTA effects on kinesin binding
to membranes were at least partially additive suggests that multiple
pathways may exist to release kinesin from MBOs and become activated
during standard homogenization protocols.
|
The ability of NEM and EDTA to inhibit release of kinesin from MBOs
suggested an active process but did not identify the cellular components responsible. Immunochemical studies had implicated KLCs in
kinesin binding to vesicles (Hirokawa et al., 1989
; Stenoien and Brady, 1997
), so the KLC primary sequence was examined for motifs
that might be involved in regulation of membrane binding. The central
domain of KLC contains five imperfect tandem repeats of 42 amino acids
each (Cyr et al., 1991
). These repeats have a high degree of
similarity to each other and are conserved to an unusually high degree
(>95% identity) across species (Brady, 1995
; Stenoien and Brady,
1997
). Our previous work had implicated these tandem repeat domains in
kinesin binding to MBOs, because an antibody (KLC-ALL) directed
against the repeat domain released kinesin from isolated vesicles in
vitro and inhibited fast axonal transport. As a result, KLC tandem
repeat domains were thought to mediate protein-protein or
protein-lipid bilayer interactions needed for kinesin binding to MBOs
(Stenoien and Brady, 1997
).
Analysis of KLC sequences (Figure 4)
revealed that tandem repeat domains contain conserved sequences
characteristic of the "J-domain" motif first described in DnaJ
(Tsai and Douglas, 1996
). The predicted structure of the tandem repeat
domains (Cyr et al., 1991
) was also consistent with a
J-domain function (Hill et al., 1995
; Kelley, 1998
). The
hallmarks of a J-domain are a tripeptide HPD sequence between two alpha
helical-rich stretches (Figure 4), creating a finger-like structure
that can interact with members of the hsp70 chaperone family. A variety
of proteins have been found to contain J-domains, several of which
mediate processes involving protein-membrane interactions and
molecular chaperones (Cyr et al., 1994
; Kelley, 1998
). This
suggested that an hsp70 chaperone might bind to KLC. The action of
hsp70 proteins on kinesin-MBO interactions was tested by evaluating
the in vitro ability of hsc70 to release kinesin from purified vesicle
fractions (Figure 5). Purified V2
vesicles were incubated with or without hsc70 for 30 min at 37°C.
Only 5% of vesicle-associated kinesin was released into the
supernatant by incubation with buffer alone. In contrast, ~50% of
bound kinesin was released from vesicle surfaces by in vitro
incubations with hsc70 and ATP (Figure 5a). This is likely to be an
underestimate of kinesin releasable by hsc70, because vesicle fractions
used for these assays were purified by standard cell fractionation
methods. Kinesin release by hsc70 during homogenization is likely to be
more extensive, because much endogenous membrane-bound kinesin was lost
during purification (Figures 2 and 3). The effect of ATP alone was also
assayed, because ATP is required for hsc70 function. Approximately 12%
of kinesin was released into the supernatant of the sample after
incubation with buffer plus ATP in the absence of added hsc70 (Figure
5). This ATP-dependent release probably resulted from hsc70
contamination of vesicle fractions, because a small amount of hsc70 was
consistently detectable in immunoblots of the vesicle
fractions (see Figure 3). Moreover, immunoblots with
anti-hsc70 antibody showed release of endogenous hsc70 from samples
only in the presence of added ATP (our unpublished data).
|
|
The roles of divalent cations and ATP hydrolysis in release of
vesicle-bound kinesin by hsc70 were assessed because hsc70 function
requires Mg++-dependent hydrolysis of ATP
(Wilbanks et al., 1994
). Addition of millimolar EDTA in the
absence of added Mg++ significantly reduced the
amount of kinesin released by hsc70/ATP to ~20% (Figure 5a). This
was consistent with observations that EDTA increased the amount of
kinesin retained by MBOs during homogenization (Figure 3). Under the
conditions of the assay, EDTA did not completely inhibit, probably as a
result of residual divalent cations present in the vesicle fraction and
added ATP. Efficiency of release was also reduced by incubation with
either AMP-PNP or adenosine
5'-[
,
-methylene]triphosphate, two nonhydrolyzable
analogues of ATP. Both ATP analogues reduced hsc70-mediated release of
kinesin from vesicles to ~30% (Figure 5a). Neither of these
analogues bind tightly to hsc70 but act as weak competitive inhibitors
in the presence of residual ATP from vesicle fractions. Together, these
results indicate that binding and hydrolysis of MgATP is required for
hsc70-mediated release of kinesin from MBOs.
Release of membrane-bound kinesin by hsc70 was also
sensitive to NEM in vitro (Figure 5b). When 2 mM NEM and hsc70 were
added at the same time (time 0), kinesin release by hsc70 was
effectively blocked. This block required alkylation of a sulfhydryl by
NEM because addition of comparable amounts of NEM inactivated by DTT at
time 0 had no effect on release of kinesin by hsc70. However, addition
of NEM to samples at various times after addition of hsc70 generated a
time course for kinesin release (Figure 5b). Adding NEM >20 min after
hsc70 did not affect the amount of kinesin released into supernatant,
but clear decrements in kinesin release resulted if NEM was added
10
min after starting hsc70 incubation. If vesicle fractions were
pretreated with 5 mM NEM and excess NEM was neutralized by addition of
excess DTT before addition of hsc70, hsc70 was no longer able to
release kinesin from vesicle fractions (Figure 5b). In contrast, a
similar pretreatment of hsc70 with NEM had no effect on its ability to
release kinesin from vesicles. Thus, the NEM-sensitive component
required for hsc70 release of kinesin must be an MBO-associated component.
To characterize interactions between KLC and hsc70 further, fusion
proteins containing different KLC constructs were added to the kinesin
release assay. Four different bacterially expressed GST fusion proteins
were used: 1) GST-LCA contains full-length KLC A fused to GST; 2)
GST-TR1 contains KLC tandem repeat amino acids 238-321 fused to GST;
3) GST-TR2 contains KLC tandem repeat amino acids 238-488 fused to
GST; and 4) GST alone was used as a control in these assays. GST-LCA,
GST-TR1, and GST-TR2 all inhibited release of kinesin by hsc70, but GST
alone was ineffective (Figure 6a).
GST-TR1 and GST-TR2 were more effective than GST-LCA in inhibiting kinesin release by hsc70 (Figure 6a). Differences in degree of inhibition between GST-LCA and GST-TR1/TR2 raised the possibility of
negative cooperativity between tandem repeats and other KLC domains.
When the abilities of GST-LCA and GST-TR1 to inhibit kinesin release
was tested at various molar ratios (Figure 6b), both GST-LCA and
GST-TR1 approached saturation at a 1:1 molecular ratio to hsc70.
However, GST-TR1 was more effective at inhibiting kinesin release than
GST-LCA at all molar ratios. GST-LCA never reduced kinesin release by
hsc70 to less than half-maximal, whereas GST-TR1 almost completely
inhibited hsc70-mediated kinesin release.
|
Conformational differences between GST-LCA and
GST-TR1/TR2 that affected interactions with hsc70 could also explain
this difference. The ability of a J-domain to bind hsc70 can be
evaluated by assaying its stimulation of hsc70 ATPase activity (Cyr
et al., 1994
; Tsai and Douglas, 1996
; Greene et
al., 1998
). GST alone was inactive in hsc70 ATPase assays, but
both GST-LCA and GST-TR1 stimulated hsc70 ATPase activity to a similar
extent (Figure 6c). This indicates that tandem repeats and full-length
KLC fusion proteins were comparable in their ability to bind and
activate hsc70 ATPase. Taken together, these results suggest that KLC
J-domain motifs interact directly with hsc70. Differences between KLC
and tandem repeat domain inhibition of hsc70-mediated kinesin release
from vesicles may reflect interaction of other domains in KLC with
membrane components.
Finally, the ability of exogenous hsc70 to release kinesin from
membranes in situ was examined (Figure
7). Cells were permeabilized by
incubation with 0.01% Triton X-100 for 4 min in the presence or
absence of exogenous hsc70 before fixation. Brief incubation with hsc70
produced a consistent reduction in kinesin immunoreactivity (Figure 7,
a and b). Kinesin immunoreactivity in processes was most severely
affected, but there was also depletion of kinesin in cell bodies
relative to control cells. The fact that not all kinesin was extracted
by a short hsc70 incubation is consistent with the biochemical studies
(see Figure 5) but may also represent either a fraction of kinesin that
is resistant to hsc70 release or one that requires an additional
cofactor not preserved under these conditions.
|
| |
DISCUSSION |
|---|
|
|
|---|
The large amount of kinesin present in soluble fractions of tissue
extracts had always been at odds with its putative role as a motor for
MBOs. Moreover, homogenization data were not consistent with evidence
that kinesin was bound very tightly to vesicles (Leopold et
al., 1992
; Schnapp et al., 1992
) or with in vivo
studies that detected only vesicle-associated kinesin (Pfister et
al., 1989b
; Elluru et al., 1995
). Similarly, gentle
permeabilization of cells releases a smaller fraction of cellular
kinesin than homogenization. These observations suggested that some
membrane-associated kinesin might be actively released during
subcellular fractionations. When a variety of enzyme inhibitors were
evaluated, two chemically distinct treatments substantially increased
the amount of kinesin associated with MBOs in homogenates: NEM and
EDTA. Subcellular fractionation with these two agents suggest that
virtually all cellular kinesin is associated with MBOs, so that the
removal, and possibly the addition, of kinesin to vesicles are likely
to be active, highly regulated processes.
The action of these agents is consistent with other elements of
membrane trafficking in cells. Previous studies showed that alkylation
of free sulfhydryls by NEM inhibits a number of cellular processes
associated with membranes, including vesicle fusion (Rothman, 1994
; Hay
and Scheller, 1997
) and posttranslational translocation of precursor
proteins into the endoplasmic reticulum (Chirico et al.,
1988
), mitochondria (Murakami et al., 1988
), or nucleus (Shi
and Thomas, 1992
). Several distinct NEM-sensitive factors appear to act
at different stages of intracellular transport pathways. At least two
NEM-sensitive components are involved in endosomal fusion (Rodriguez
et al., 1994
). A membrane-associated component is sensitive
to low levels of NEM (1 mM), whereas a second component is cytosolic
and requires higher NEM concentrations for inhibition (
3 mM). NEM
concentrations in the range of 1-2 mM had maximal effects on the
amount of membrane-associated kinesin, a concentration comparable with
that reported with the membrane-associated NEM-sensitive component in
endosomal fusion (Rodriguez et al., 1994
). Consistent with
this, pretreatment of vesicles with NEM but not pretreatment of hsc70
blocked the ability of hsc70 to release kinesin. These results suggest
that at least one membrane-associated component sensitive to low
concentrations of NEM is required for release of kinesin from MBOs
during homogenization. The identity of this membrane-associated
component is not yet known. Both kinesin heavy chain (KHC) and KLC can
be modified by NEM (Pfister et al., 1989a
) and are potential
candidates. However, washing MBOs with 1 M NaCl blocks hsc70 release of
kinesin but has little effect on kinesin binding to MBOs. This suggests
that a vesicle component other than kinesin is required for
hsc70-mediated release, and this would also be a potential NEM target.
KLCs have long been thought to participate in binding of kinesin motors
to MBOs (Hirokawa et al., 1989
; Cyr et al.,
1991
). This interpretation is reinforced by changes in KHC distribution associated with knocking out one of the KLC genes in mouse (Rahman et al., 1999
), but the molecular basis of that interaction
was not well understood. Based on actions of an antibody against KLC, the KLC tandem repeat domain was proposed to interact with receptor molecules on MBOs (Stenoien and Brady, 1997
). The presence of two
conserved HPD sequences characteristic of the J-domain in DnaJ-like proteins (Tsai and Douglas, 1996
) and similarities between the structure predicted for KLC tandem repeats and known J-domain structures (Hill et al., 1995
) suggested that KLC might
contain functional J-domains. J-domain motifs are found in a variety of polypeptides that mediate cellular processes in cooperation with hsp70
chaperone family members (Cyr et al., 1994
). Hsp70-like proteins function as molecular chaperones to mediate or facilitate a
variety of biological processes that include folding and unfolding of
proteins, formation or dissociation of protein complexes, and translocation of proteins across membranes (Hartl, 1996
; Schatz and
Dobberstein, 1996
). Significantly, many hsp70-mediated processes are
also NEM sensitive (Chirico et al., 1988
; Murakami et
al., 1988
; Shi and Thomas, 1992
), although hsp70 itself is not
sensitive to NEM. The homologies between KLC tandem repeats and
J-domain sequences suggested that a member of the Hsp70 chaperone
protein family might catalyze removal of kinesin from vesicles.
Incubating vesicles with purified hsc70 and MgATP selectively removed
tightly bound kinesin from membrane surfaces. A requirement for MgATP would explain the effects of EDTA in stabilizing kinesin association with membranes during fractionations, whereas a requirement for NEM-sensitive cofactors is consistent with NEM stabilization of kinesin binding.
The tight binding of kinesin to MBOs probably involves multiple
organelle binding domains involving both heavy and light chains of
kinesin. KLC domains such as the heterogeneous carboxyl and conserved
amino termini may play other roles, such as targeting of kinesin to a
specific type of organelle or mediating interactions between KLC and
KHC (Cyr et al., 1991
; Stenoien and Brady, 1997
). The
presence of other domains with different functions would explain why
recombinant KLC and tandem repeat fusion proteins differ in their
ability to inhibit hsc70-mediated release of kinesin from MBOs.
The KLC tandem repeat domain itself may have two functions: as a
binding domain for membrane components and as a DnaJ-like cochaperone
that recruits hsp70 to MBO surfaces for selective removal of kinesin.
Consistent with this idea, KLC tandem repeats exhibit homology not only
with J-domains but also with a tetratricopeptide repeat motif (Gindhart
et al., 1998
), a motif thought to be involved in
protein-protein interactions. The two functions for KLC may be
analogous to dual roles played by other DnaJ-like proteins.
For example, both auxilin and Sec63 regulate binding of peptide
substrates to hsp70 and stimulate hsp70 ATPase activity. Auxilin was
recently identified as a cofactor that binds hsc70 via a J-domain and
recruits hsc70 to the clathrin-coated vesicle via its clathrin binding
domain (Ungewickell et al., 1995
). When the two domains of
auxilin are expressed separately, the ability to recruit hsc70 to
coated vesicles is lost, even though each domain retains its specific
binding activity (Holstein et al., 1996
; Ungewickell et al., 1997
). Similarly, Sec63 is an integral membrane
protein in Saccharomyces cerevisiae with a lumenal DnaJ-like
region that mediates interaction with Bip, an hsp70 family member, and
promotes protein translocation into the endoplasmic reticulum. A
soluble Sec63p lumenal domain inhibited efficient precursor import into proteoliposomes (Ann and Randy, 1997
) but retained its ability to
activate hsc70.
The activities of KLC, auxilin, and Sec63P suggest that the J-domain of DnaJ-like proteins serves to regulate kinetics of peptide substrate binding and hsp70 ATPase activity, but associated domains may be required for recruiting hsp70s to specific locations. As a result, both KLC and tandem repeat fusion proteins exhibit comparable abilities to interact with hsc70, but tandem repeats alone are more efficient at inhibiting hsc70-mediated release of kinesin. Additional KLC domains present in the full-length GST-LCA may retain the ability to bind membranes containing endogenous kinesin. This effectively increases the local concentration of hsc70 near bound kinesin and facilitates release of kinesin, albeit less efficiently than if LCA were associated with a KHC. In contrast, GST-TR1/TR2 act as soluble dominant negative factors that bind hsc70 but have lost the ability to recruit hsc70 to kinesin on a vesicle surface.
The complex organization of neurons and many other eukaryotic cells
requires specialized mechanisms to ensure that proteins are efficiently
transported to appropriate destinations. This implies the existence of
specific targeting mechanisms, but once an organelle has reached the
correct destination, mechanisms must exist to prevent continued
translocation. Previous investigations on regulation of kinesin motors
assumed that posttranslational modifications would be involved (Bloom
et al., 1993
; Lee and Hollenbeck, 1995
; Okada et
al., 1995
). Unfortunately, despite extensive study, no biochemical
switch has been found to turn off kinesin motor activity. Although such
pathways may exist, an alternative mechanism to prevent an MBO from
translocating farther is removal of kinesin from MBOs. Cytoplasmic
hsc70 was found to release kinesin from vesicles in a
nucleotide-dependent and NEM-sensitive manner in vitro. These results
suggest that members of the hsp70 chaperone family might have a role in
regulating delivery of axonally transported materials in vivo to the
proper sites by releasing motor proteins from their cargoes in specific
subcellular regions.
An attractive corollary to this hypothesis is that a reciprocal
relationship may exist between clathrin-coated vesicles and kinesin
transport vesicles (Figure 8). For
example, cellular locations in neurons with high levels of coated
vesicle assembly and disassembly are places either where kinesin is
thought to be added to an MBO (i.e., post-Golgi formation of transport
vesicles) or where kinesin is removed from an MBO (i.e., presynaptic
terminals) (Maycox et al., 1992
). Studies on axonal
transport of clathrin and hsc70 are consistent with this idea (Garner
and Lasek, 1981
; Gower and Tytell, 1987
; de Waegh and Brady, 1989
;
Black et al., 1991
). Very little clathrin is detectable
moving with MBOs in fast axonal transport (Black et al.,
1991
). Instead, the bulk of clathrin and associated coated vesicle
proteins move as part of slow axonal transport (Garner and Lasek, 1981
;
Gower and Tytell, 1987
; Black et al., 1991
). Similarly,
hsc70 moves as part of slow axonal transport (de Waegh and Brady,
1989
), and coated vesicle proteins coimmunoprecipitate with hsc70
(Black et al., 1991
). Coated vesicle proteins and hsc70 must
form a stable complex in axons that is dissociated in presynaptic terminals or other domains with active recycling of membrane proteins (see Figure 8). Axonal hsc70 bound to clathrin coat proteins would not
be available to act on kinesin, but hsc70 in presynaptic terminals with
active membrane recycling would be able to act on kinesin. Such a model
for hsc70 action provides a mechanistic link between kinesin binding to
MBOs and other stages of vesicle trafficking. Regardless, the highly
conserved amino acid sequence of KLC tandem repeat domains establishes
that this motif has an essential function. The ability of hsc70 to bind
tandem repeats and release kinesin from vesicles suggests that control
of kinesin binding to membranes represents such an essential function.
|
| |
ACKNOWLEDGMENTS |
|---|
We thank H. Ross Payne, Robin Wray, Zhao Min, and Pilar Coffee for technical assistance during these studies. Preparation of this manuscript was supported in part by grants from the National Institute of Neurological Disease and Stroke (NS-23868 and NS-23320), the National Institute of Aging (AG-12646), the National Aeronautics and Space Administration (NAG2-962), and the Welch Foundation (1237).
| |
FOOTNOTES |
|---|
* Corresponding author. E-mail address: Scott.Brady{at}emailswmed.edu.
| |
REFERENCES |
|---|
|
|
|---|
S inhibits organelle transport along axonal microtubules.
J. Cell Biol.
120, 467-476